These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34667063)

  • 1. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report.
    Ardalan B; Azqueta JI; England J; Eatz TA
    Cold Spring Harb Mol Case Stud; 2021 Oct; 7(5):. PubMed ID: 34667063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma.
    Ecker BL; Tao AJ; Janssen QP; Walch HS; Court CM; Balachandran VP; Crane CH; D'Angelica MI; Drebin JA; Kingham TP; Soares KC; Iacobuzio-Donahue CA; Vakiani E; Gonen M; O'Reilly EM; Varghese AM; Jarnagin WR; Wei AC
    Clin Cancer Res; 2023 Apr; 29(7):1368-1374. PubMed ID: 36795432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful BRAF/MEK inhibition in a patient with
    Busch E; Kreutzfeldt S; Agaimy A; Mechtersheimer G; Horak P; Brors B; Hutter B; Fröhlich M; Uhrig S; Mayer P; Schröck E; Stenzinger A; Glimm H; Jäger D; Springfeld C; Fröhling S; Zschäbitz S
    Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.
    Xavier CB; Marchetti KR; Castria TB; Jardim DLF; Fernandes GS
    J Gastrointest Cancer; 2021 Mar; 52(1):374-380. PubMed ID: 33225411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.
    Wang Y; Wang B; Xiang L; Deng J; Xu B; He P; Pu W; Wang H; Fan Y; Chen H
    Front Immunol; 2022; 13():1016647. PubMed ID: 36311715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
    Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.
    O'Reilly EM; Hechtman JF
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii36-viii40. PubMed ID: 31605106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes.
    Oliverius M; Flasarova D; Mohelnikova-Duchonova B; Ehrlichova M; Hlavac V; Kocik M; Strouhal O; Dvorak P; Ojima I; Soucek P
    Mutagenesis; 2019 Dec; 34(5-6):403-411. PubMed ID: 31375828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.
    Singh H; Keller RB; Kapner KS; Dilly J; Raghavan S; Yuan C; Cohen EF; Tolstorukov M; Andrews E; Brais LK; da Silva A; Perez K; Rubinson DA; Surana R; Giannakis M; Ng K; Clancy TE; Yurgelun MB; Schlechter BL; Clark JW; Shapiro GI; Rosenthal MH; Hornick JL; Nardi V; Li YY; Gupta H; Cherniack AD; Meyerson M; Cleary JM; Nowak JA; Wolpin BM; Aguirre AJ
    Clin Cancer Res; 2023 Nov; 29(22):4627-4643. PubMed ID: 37463056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
    Rémond MS; Pellat A; Brezault C; Dhooge M; Coriat R
    ESMO Open; 2022 Dec; 7(6):100638. PubMed ID: 36399952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response in
    Campoverde LE; Batalini F; Bulushi Y; Bullock A
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35487638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
    Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
    J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
    Baechmann S; Ormanns S; Haas M; Kruger S; Remold A; Modest DP; Kirchner T; Jung A; Werner J; Heinemann V; Boeck S
    BMC Cancer; 2017 May; 17(1):374. PubMed ID: 28549417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
    Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
    Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
    Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
    Guren TK; Thomsen M; Kure EH; Sorbye H; Glimelius B; Pfeiffer P; Österlund P; Sigurdsson F; Lothe IMB; Dalsgaard AM; Skovlund E; Christoffersen T; Tveit KM
    Br J Cancer; 2017 May; 116(10):1271-1278. PubMed ID: 28399112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
    Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
    Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.